

The aim of the presentation is to show how Selvita became multinational biotech company



Cracow University of Economics  
Agata Kubajka  
Gabriela Kukla  
Magdalena Kurcz




## INNOVATIVE PROJECTS

### SEL120:

Selvita's second largest project for the treatment of AML and other rare oncological diseases worth 130 million PLN

September 2019 - first clinical research (first patient)



### SEL24

First of the most advanced project currently investigated for the treatment of Acute Myeloid Leukemia

March 2017 – first-in-human entered

## POZNAŃ

Contract with the Adam Mickiewicz University in Poznań for renting laboratories in the buildings of the Wielkopolska Center of Advanced Technologies

## SAN FRANCISCO

Selvita Inc. with head office in Cambridge, Massachusetts - renewal of cooperation contract from 2016 with University of California in San Francisco (UCSF) for next 3 years.

## UNIVERSITIES



## BOSTON

Greater Boston Area the first foreign office in the neighborhood of Massachusetts Institute of Technology, Harvard University and medical centers

## CAMBRIDGE

Cambridge cooperation from 5th of May 2015 is focused on supporting and developing business relationships with local partners

Selvita's competitive advantage is a result of its activity in highly innovative area. Biotechnology segment is advanced technology and being its leader is an incredible success for small start-up from Cracow.